$Bob's and Jbem's Bitchin' Bios

[buckiii2]

MICT. I took a long position today. Thanks Ash for the DD. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136900906

[buckiii2]

MGTI news. http://www.mgtci.com/newsroom/news/mgt-capital-completes-comprehensive-financial-restructuring-300572008.html

[toomorrow]

$GAHC - watch for $OWCP type move in January.

Blockchain with voting technology. Patent for voting blockchain just approved last week not priced in. Financial statements are all current and older ones have recently had updates (someone looking them over carefully). Acquisition target disclosed in recent filing.

Blockchain technology is a paradigm shift akin to the internet and desktop computer.

Expect big moves in pps in 2018. This is a buy and hold.

Do your own DD and buy at your own risk.

[buckiii2]

Another form 4 buy the 13th. https://ih.advfn.com/p.php?pid=nmona&article=76290876&symbol=NURO

[buckiii2]

XPLR Form 4 buy. https://ih.advfn.com/p.php?pid=nmona&article=76282198&symbol=XPLR

[buckiii2]

NURO another form 4 buy.watch for MA50 break http://stockcharts.com/h-sc/ui?s=NURO ;

[TheFinalCD]

Positive Clinical Results News!! https://ih.advfn.com/p.php?pid=nmona&article=76277046 https://finviz.com/quote.ashx?t=PTI

[buckiii2]

NURO. Another form 4 buy. https://ih.advfn.com/p.php?pid=nmona&article=76271865&symbol=NURO

[buckiii2]

ZIOP. https://globenewswire.com/news-release/2017/11/01/1172336/0/en/ZIOPHARM-Announces-Five-Abstracts-Accepted-for-Presentation-at-the-2017-American-Society-of-Hematology-Annual-Meeting.html

[buckiii2]

XPLR form 4 buys. https://ih.advfn.com/p.php?pid=nmona&article=76261854&symbol=XPLR

[buckiii2]

NURO Friday 2 more form 4 buys. https://ih.advfn.com/p.php?pid=nmona&article=76262138&symbol=NURO

[buckiii2]

NURO two Form 4 buys after hours.

[georgejjl]

Watch IPIX tomorrow!!!

Formal collaboration with pharmaceutical companies that have expressed an interest in partnering Brilacidin-OM may well assist further with expediting the drug candidate’s development timetable. Some of these partnering conversations have matured to the point of potentially structuring mutually beneficial licensing agreements, pending the final Phase 2 study results.

http://www.ipharminc.com/press-release/2017/11/16/innovation-pharmaceuticals-offers-perspectives-on-brilacidin-as-a-potential-preventative-treatment-for-oral-mucositis-in-head-and-neck-cancer-patients

Good luck and GOD bless,

George

[TheFinalCD]

CUR running NOW on P2 NEW$ https://finance.yahoo.com/news/neuralstem-presents-positive-updated-data-120000052.html

[buckiii2]

XGTI new form 4 buy. https://ih.advfn.com/p.php?pid=nmona&article=76213950&symbol=XGTI

[buckiii2]

NURO. Form 4. https://ih.advfn.com/p.php?pid=nmona&article=76214184&symbol=NURO

[buckiii2]

ZIOP. https://www.investorvillage.com/smbd.asp?mb=16353&mn=92761&pt=msg&mid=17751869

[buckiii2]

XPLR. As of the close of business on October 23, 2017, the record date for the Annual Meeting, there were 11,020,905 shares of the Company’s common stock issued and outstanding and entitled to vote at the Annual Meeting.

[buckiii2]

ZIOP. https://finance.yahoo.com/news/viruses-problem-car-t-drugmakers-123000751.html

[buckiii2]

FDA. https://www.google.com/amp/s/www.bloomberg.com/amp/news/articles/2017-11-30/fda-aims-to-expand-early-approval-program-for-promising-drugs

[buckiii2]

NURO. NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell® device usability by improving performance for users that maintain an active lifestyle.
"We are pleased to have received this latest patent, which expands the Quell intellectual property portfolio. The ability to easily and intuitively interact with the Quell device is important to Quell users as daily use is correlated with better results. The technology in this patent helps Quell meet the needs of even the most active users,” said Shai N. Gozani, M.D., Ph.D.
About Quell
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a clinical study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.

[buckiii2]

XGTI.
xG Technology Awarded Contract to Provide Interference Mitigation Technology under Government Shared Spectrum Research Progra...
Print
Alert
XG Technology, Inc. (NASDAQ:XGTI)
Intraday Stock Chart
Today : Wednesday 29 November 2017

Click Here for more XG Technology, Inc. Charts.
SARASOTA, Fla., Nov. 29, 2017 /PRNewswire/ -- xG Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a leading provider of wireless video solutions to broadcast, law enforcement and defense markets, and private mobile broadband networks for critical communications, announced that it has been awarded a subcontract from Leidos to provide interference mitigation solutions and simulation models under a Defense Advanced Research Projects Agency (DARPA) shared spectrum research program.


The award leverages xG Technology's innovations in software defined cognitive radio (SDCR) platforms, and expertise in developing architectures that better enable spectrum sharing and significantly enhance interference mitigation.
The program seeks to develop spectrum sharing technologies that enable access and mitigate the impact of spectrum congestion. This congestion is a growing problem and limits operational capabilities due to the increasing bandwidth demands for wireless communications, the use of net-centric and unmanned systems, and the need for increased flexibility in communications.
"xG's contributions to this program in the area of interference mitigation reflect xG's growing capabilities in supporting government programs in this area," said John Coleman, President of xG's Federal Business Unit. "Our support of this program reflects our leading position in interference mitigation, spectrum sharing technologies, and high reliability communications systems and associated research."

[buckiii2]

XGTI form 4. https://ih.advfn.com/p.php?pid=nmona&article=76184797&symbol=XGTI

[buckiii2]

XPLR.
Louisiana Department of Environmental Quality Inspectors Go Fully Paperless with Xplore’s HazLoc-Certified Rugged Tablets

Xplore Technologies Corp. (NASDAQ:XPLR) today announced that inspectors with the Louisiana Department of Environmental Quality (DEQ) are now using the Xplore XSLATE B10 fully rugged tablets as their primary workstation in the office, vehicle and field. The State agency wanted to transition its field team to a fully paperless operating environment, and Xplore’s C1D2-certified Windows® tablets were the only mobile computers in their class that could safely be used in vehicle as well as in-hand at inspection sites where combustible gasses and flames are present.
Louisiana’s state inspectors are responsible for routinely monitoring gas stations, refineries, chemical plants, underground wells, landfills and other sites where environmental quality protections are mandated. They are also dispatched to ‘ground zero’ after fires, spills and other emergencies where there’s often an elevated presence of hazardous material.
“Knowing there is an inherent risk with bringing electronic devices around volatile substances, we have to ensure that any mobile device we give them meets strict Hazardous Location use standards,” explained Jason Hanchey, business analytics specialist, Office of Management and Finance, State of Louisiana. “We feel very comfortable sending them into the field with the XSLATE B10 rugged tablet given its intrinsic safety features. Plus, the tablet makes it much easier to examine infrastructure integrity and air, ground, and water quality in time-sensitive situations.”
The Louisiana DEQ is using the XSLATE B10 rugged tablets to immediately collect results from soil sample, groundwater, radiation level and plant stack tests using digitally fillable versions of its standard inspection forms. Inspectors then submit the findings to the site representative, as well as the department’s back-office system for official recording, in real-time. This eliminates the risk of lost reports, transcription errors and remediation delays.
“Our inspectors are notorious for their messy handwriting, and there were many times where they could not read what they had written on the carbon-copy inspection report when they got back to the office,” Hanchey continued. “That is no longer a problem thanks to the easy data inputs and expedited report submissions facilitated by the Xplore rugged tablet.”
The Intel®-powered XSLATE B10 and Office Dock combination also provide the ideal desktop configuration for these inspectors when they were in the office. This has allowed the Department of Environmental Quality to standardize on a single PC platform for all job sites without compromising on computing capabilities. The rugged tablet meets the State’s very strict security, performance and connectivity criteria, which is critical considering all highly sensitive data related to inspection activities is now being captured and recorded via electronic methods only.
“Louisiana’s inspectors spend their days executing a comprehensive environmental fortification program that protects the public’s health, safety and welfare,” commented John Graff, vice president of marketing at Xplore. “That is why we worked closely with the DEQ to ensure our rugged tablet-based solutions provide both a reliable computing platform and a scalable solution to support their growing inspection demands.”
For more information about the XSLATE B10 fully rugged tablet, please visit www.xploretech.com/XSLATEB10. To learn about Xplore’s mobility solutions for government organizations, visit www.xploretech.com/government. Additional guidance about the safe use of mobile computers in Hazardous Locations can be found at www.xploretech.com/HazLoc.

[bigcat2]

ONCS - What is the timeline for this play? When will next results come out?

Seems obvious it will pop again in the next 3-6 months since they have enough cash now..

[buckiii2]

ZIOP. https://www.bizjournals.com/boston/news/2017/11/20/ziopharm-says-its-brain-cancer-drug-helped-trial.html

[buckiii2]

VICL new 13g. 9.2%. https://ih.advfn.com/p.php?pid=nmona&article=76135058&symbol=VICL

[buckiii2]

XGTI. https://ih.advfn.com/p.php?pid=nmona&article=76131995&symbol=XGTI

[buckiii2]

Awesome news on the 1st abstract
None of the 4 patients in low dose has died and the one in the mid steroid group is alive at 11 months.

The 4 low dose are alive at 9.5, 10, 11 and 23.5 months. That is proof that IL-12 is working.

Very important news. The 12.5 months survival ignores the 4 patients alive at less than 12.5 months. The 4 are at 9.5 to 11 months. So the survival will be more than 12.5 months my Jan 2018 and it is impossible to know how much higher it will go.

The low dose could be over 12.5 months before one of the 4 die. Amazing to imagine what the survival data will look like when the trial ends.

This all bores well for phase 3.

http://www.ziopharm.com/content/02-pipeline/03-presentations-publications/1-22nd-annual-meeting-and
-education-day-of-the-society-for-neuro-oncology-sno-in-san-francisco/2-phase-1-study-of-ad-rts-hil-
12-veledimex-in-adult-recurrent-glioblastoma/2017sno_chiocca_ph1studyad-rts-hil-12veladultrgbm.pdf

[buckiii2]

ZIOP presenting at SNO this weekend.
AdRTShIL12 Plus Veledimex Presentations at SNO 2017 Poster Oral Presentation Oral PresentationPhase 1 Study of Ad RTShIL Veledimex12 plus in Pediatric Brain Tumors Stewart Goldman Lurie Children’s HospitalA Phase 1 study of Ad RTShIL veledimex , M.D., 12 + in adult recurrent glioblastoma Antonio Chiocca , M.D., Ph.D., Brigham and Women’s / Dana Cancer CenterFarber Controlled Expression of IL 12 Improves Survival in Glioma by Activating the Immune Response in Mice and Humans John A. Barrett , ZIOPHARM Conference call following SNO. Details to follow Ph.D., Oral Presentation Controlled Local Expression of IL12 as Gene Therapy Concomitant with Systemic Chemotherapy Improves Survival in Glioma John A. Barrett ZIOPHARM , Ph.D., Third Quarter 2017 Financial Results and Updates on Recent Activities

[buckiii2]

VICL. https://ih.advfn.com/p.php?pid=nmona&article=76125480&symbol=VICL

[buckiii2]

XGTI. Integrated Microwave Technology LLC,* Hackettstown, New Jersey, has been awarded a $12,583,035 firm-fixed-price, foreign military sales (Afghanistan) contract for the purchase of hand-held intelligence, surveillance and reconnaissance receiver devices. Bids were solicited via the Internet with eight bids received. Work locations and funding will be determined with each order, with an estimated completion date of Sept. 24, 2020. The 408th Contracting Support Brigade, Regional Contracting Center, Qatar, is the contracting activity (W912D2-18-D-5000).

2016
https://www.prnewswire.com/news-releases/xg-technology-completes-purchase-of-integrated-microwave-technologies-llc-300212653.html

[TheFinalCD]

Breaking News
Egalet's abuse-deterrent oxycodone safe in long-term study; shares up 81%
Results from a Phase 3 study assessing the safety of Egalet's (EGLT +80.7%) abuse-deterrent oxycodone, Egalet-002, showed the opioid to be safe and well-tolerated with the incidence of adverse events consistent with an extended-release oxycodone.The open-label 281-subject study evaluated the safety and tolerability of Egalet-002 for up to 56 weeks in opioid-experienced patients with moderate-to-severe chronic noncancer pain. About 150 participants received Egalet-002 for six months while ~50 received it for one year.Another Phase 3 assessing the safety and efficacy of Egalet-002 in chronic pain patients will wind up next month.Egalet-002 incorporates the company's Guardian Technology which uses injection molding to create a hard matrix designed to make the pill difficult to crush, grind, chew or dissolve. It also turns to gel when exposed to water.
Today, 3:26 PM |11 Comments
https://seekingalpha.com/news/search?query=eglt

[buckiii2]

NURO form 4. https://ih.advfn.com/p.php?pid=nmona&article=76115687&symbol=NURO

[UHD]

VBIV, time is now imo

VBIV, Analyzing VBI Vaccines (VBIV) and Trillium Therapeutics (TRIL)

https://www.google.com/amp/s/stocknewstimes.com/2017/11/15/analyzing-vbi-vaccines-vbiv-and-trillium-therapeutics-tril.html/amp

[buckiii2]

Thanks for your service to all Honorably Discharged Veterans!

[buckiii2]

Title: Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1

Poster Number: P524

Lead Author: Alain Algazi, MD, Associate Professor, Department of Medicine (Hematology/Oncology), UCSF

Date and Time: Saturday, November 11th, 12:30-2:00 p.m. and 6:30-8:00 p.m.

[buckiii2]

OUT NOW!

http://oncosec.com/wp-content/uploads/2017/11/ONCS-SITC-POSTER-2017_-1.pdf

[buckiii2]

ONCS. H.C. Wainwright's Ram Selvaraju anticipates ONCS could apply with Phase IIb data for Breakthrough Therapy designation.

Julie Lamb, Senior Editor-November 10, 2017, 10:24 AM EDT

https://www.smarteranalyst.com/2017/11/10/heres-bull-sees-next-oncosec-medical-inc-oncs-back-phase-ii-combination-trial-success/

[BottomBounce]

$KNDI Chart. Elliot Wave

[buckiii2]

ONCS news. https://ih.advfn.com/p.php?pid=nmona&article=76057324&symbol=ONCS

[buckiii2]

ONCS. Analyst Event in National Harbor, MD

OncoSec will host an analyst and investor event with clinical investigators on Friday, November 10, 2017 at 7:00 a.m. EST in National Harbor, MD during the 2017 Society of Immunotherapy for Cancer Annual Meeting. The event will include a presentation and discussion of updated clinical data for the company's ImmunoPulse IL-12 program, highlighting the global, registration-directed PISCES/KEYNOTE-695 trial. The event will be held in-person and via live webcast.

Investors and analysts are invited to listen to a live audio webcast of the presentation. To access the audio broadcast, please dial [phone] and enter the conference ID number 4938639. To join via webcast, please use the following link: https://edge.media-server.com/m6/p/aj3vpts5. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec's website: http://ir.oncosec.com/events-presentations.

For those interested in attending this event in person, please contact [e-mail]. Please RSVP in advance as seating is limited.

[TheFinalCD]

Otonomy's Otividex successful in second late-stage Ménière’s study; shares up +136% after hours

Nov. 8, 2017 4:52 PM ET|About: Otonomy (OTIC)|By: Douglas W. House, SA News Editor
A Phase 3 clinical trial, AVERTS-2, assessing Otonomy's (NASDAQ:OTIC) OTIVIDEX in patients with Ménière’s disease achieved its primary endpoint of the number of vertigo days compared to placebo. Specifically, patients in the treatment group experienced an average reduction of 6.2 vertigo days from baseline to month 3 compared to an average reduction of 3.7 days for placebo (p=0.029).

The company plans to review the data with the FDA and the requirements for a marketing application for the indication.

An earlier Phase 3, AVERTS-1, failed to achieve the primary endpoint and any of the secondary endpoints due, in large part, to a higher-than-expected placebo response.

OTIVIDEX (formerly OTO-104), a sustained-exposure formulation of the steroid dexamethasone, was being developed to treat a range of balance and hearing disorders. It is administered directly into the middle ear via injection through the eardrum. The company stopped development and reduced headcount after AVERTS-1.

Shares are up 136% after hours on robust volume.

Previously: Otonomy restructures after Otividex flop; 1/3 of non-commercial workforce cut; shares up 1% premarket (Sept. 13)

Previously: Otonomy's Otividex flunks late-stage study in Ménière’s disease (Aug. 30)
https://seekingalpha.com/news/3310123-otonomys-otividex-successful-second-late-stage-meniere-s-study-shares-136-percent-hours

[buckiii2]

OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pem...
Print
Alert
OncoSec Medical Incorporated (NASDAQ:ONCS)
Intraday Stock Chart
Today : Wednesday 8 November 2017

Click Here for more OncoSec Medical Incorporated Charts.
SAN DIEGO, Nov. 8, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec" or "Company") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced positive updated long-term follow-up data from its Phase 2 OMS I-102 combination study of ImmunoPulse® IL-12 and pembrolizumab in patients unlikely to respond to anti-PD-1 therapy. The updated data will be presented in an oral poster presentation (P524) by Dr. Alain Alagzi at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD on November 10th, 2017 at 12:45 p.m. EST.
The updated clinical and correlative immune-focused biomarker data demonstrated a 57% progression free survival (PFS) rate at 15 months with 100% (11/11) duration of response and median PFS not yet reached. Building upon previously reported data of a best overall response rate (BORR) of 50% (41% complete response [CR] rate), the updated data further demonstrate that the combination of these therapies can prime a coordinated innate and adaptive immune response, and strongly suggests a synergistic relationship with anti-PD-1. The latest findings further demonstrate that this combination approach can reshape the tumor microenvironment, yielding a robust intratumoral and systemic anti-tumor response converting "cold" tumors to "hot," potentially improving clinical outcomes in patients predicted to not respond to anti-PD-1 therapy.
"Overall, the Phase 2 trial results, including progression free survival beyond two years in multiple patients, duration of response, best overall response rate, and tolerability of the combination, provide a strong and consistent theme across multiple endpoints, underscoring the promise of ImmunoPulse IL-12 plus pembrolizumab as a viable treatment option for patients diagnosed with metastatic melanoma," said Dr. Alain Algazi, Lead Trial Investigator, Associate Professor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.
Dan O'Connor, CEO of OncoSec noted: "The robust PFS benefit and tolerability observed with ImmunoPulse IL-12 plus pembrolizumab is the first demonstrating efficacy in a predicted PD-1 non-responder population and shows that the combination represents a potentially important addition to the treatment landscape for metastatic melanoma patients who have progressed or are progressing on anti-PD-1 therapy."
The full abstract is available and can be viewed on the STIC website at www.sitcancer.org. The poster is available in the Publications section of OncoSec's website.
Analyst Event in National Harbor, MD

OncoSec will host an analyst and investor event with clinical investigators on Friday, November 10, 2017 at 7:00 a.m. EST in National Harbor, MD during the 2017 Society of Immunotherapy for Cancer Annual Meeting. The event will include a presentation and discussion of updated clinical data for the company's ImmunoPulse IL-12 program, highlighting the global, registration-directed PISCES/KEYNOTE-695 trial. The event will be held in-person and via live webcast.
Investors and analysts are invited to listen to a live audio webcast of the presentation. To access the audio broadcast, please dial [phone] and enter the conference ID number 4938639. To join via webcast, please use the following link: https://edge.media-server.com/m6/p/aj3vpts5. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec's website: http://ir.oncosec.com/events-presentations.
For those interested in attending this event in person, please contact [e-mail]. Please RSVP in advance as seating is limited.
Peer-Reviewed Publication

The findings published in Immunotherapy provide an overview of OncoSec's preclinical and Phase 1 clinical data demonstrating that ImmunoPulse IL-12 plus electroporation is safe and well-tolerated by patients. Many patients do not respond to anti-PD-1 therapies alone, representing a significant unmet medical need. ImmunoPulse IL-12 has shown to increase intratumoral lymphocyte infiltration, pro-inflammatory cytokines and TH1 immune responses, potentially boosting the activity of PD-1 antibodies without significant systemic toxicity.
For the full-article please visit, https://www.ncbi.nlm.nih.gov/pubmed/29064334.
About the SITC Annual Meeting

The Society for Immunotherapy of Cancer (SITC) is a non-profit medical professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Currently, SITC has nearly 1,600 members representing 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer. The 32nd SITC Annual Meeting & Associated Programs will take place November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, MD. For more information, please go to http://www.sitcancer.org/2017.
About PISCES/KEYNOTE-695

PISCES/KEYNOTE-695 is a global, multicenter phase 2b, open-label trial of intratumoral plasma encoded IL-12 (tavokinogene telseplasmid or "tavo") delivered by electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma who have progressed or are progressing on either pembrolizumab or nivolumab treatment. The Simon 2-stage study of intratumoral tavo plus electroporation in combination with pembrolizumab will enroll approximately 48 patients with histological diagnosis of melanoma with progressive locally advanced or metastatic disease defined as Stage III or Stage IV. The primary endpoint will be the Best Overall Response Rate (BORR).
About OncoSec Medical Incorporated

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12 (tavokinogene telseplasmid [pIL-12] or "tavo"). In Phase 1 and 2 clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.
University of California Disclaimer

The information stated above was prepared by OncoSec Inc. and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of OncoSec, or any of its products, by The Regents of the University of California, its officers, agents and employees.
Cautionary Note Regarding Forward-Looking Statements

This press release contains "

[buckiii2]

I agree. He has a pretty good resume.

[nsomniyak]

Looks like a good change to me for ONCS - new CEO is more of a deal-maker, old CEO more of a scientist?

[buckiii2]

ONCS news, new CEO.

[buckiii2]

ATRS. Valentine's Day 2018: PDUFA date

It was expected to be this month and it was moved to Feb. 14th, 2018

2018-02-14
ATRS Makena - auto injector $1.82
sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review

https://www.biopharmcatalyst.com/calendars/pdufa-calendar#ATRS

[buckiii2]

ATRS. EWING, NJ, November 7, 2017 -- Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and
financial results for the third quarter ended September 30, 2017. The Company reported record
revenue of $15.1 million and a net loss per share of $0.03 for the three months ended September 30,
2017. For the nine months ended September 30, 2017, the Company reported revenue of $40.5
million and a net loss per share of $0.08.
“We are very pleased with the progress of our quarterly financial results as Antares today reported
record revenue driven by a significant increase in product sales, specifically OTREXUP and
Sumatriptan Injection,” said Robert F. Apple, President and Chief Executive Officer of the Company.
He continued, “In the development area, we are disappointed with the outcome of the review of the
XYOSTED new drug application and the delay of the potential product launch. We continue to believe
that we have a viable product in XYOSTED and will be requesting a meeting with the U.S. Food and
Drug Administration to understand and resolve the deficiencies noted in the Complete Response
Letter, and agree upon a path forward for a potential approval.”
Third Quarter 2017 and Recent Highlights
? Reported third quarter 2017 revenue of $15.1 million, loss per share of $0.03 and cash, cash
equivalents and short-term investments of $37.4 million at September 30, 2017.
? OTREXUP® revenue grew 18% sequentially versus the second quarter of 2017 and 18%
versus the third quarter of 2016.
? Sumatriptan Injection USP total prescriptions increased to a 27% share of the migraine auto
injector market in the third quarter of 2017, up from 26% in the second quarter of 2017
according to data from Symphony Health Solutions.
? Announced the sale of the ZOMAJET™ needle-free delivery system to Ferring
Pharmaceuticals for up to $14.5 million. The transaction is subject to certain customary closing
conditions and is expected to be completed by the end of 2018.

? Received a Complete Response Letter from the U.S. Food and Drug Administration (FDA)
regarding the New Drug Application for XYOSTED™ (testosterone enanthate) injection. The
FDA cited two deficiencies related to clinical data. The next step will be to request a meeting
with the FDA to further evaluate the deficiencies and agree on a path forward for a potential

[WallStreetSTTA]

Hope everyone here didnt bitch out early on DCIX and TOPS